wehewehe
ʻO ke kumu mole mole o kēia mea waena ʻo C13H10ClN3O2S, a ʻo kona kaumaha mole 307.755.ʻO kāna hana molekala pololei e hiki ai i ka hana kūpono a me ka hoʻomaʻemaʻe kiʻekiʻe o tofacitinib.No laila,ʻo ka tofacitinib intermediate 1,4-chloro-7-p-toluenesulfonyl-7H pyrrolo [2,3-d] pyrimidine he mea nui i loko o kaʻoihana lāʻau lapaʻau e hoʻolako i ka lāʻau lapaʻau kūpono no nā maʻi autoimmune.
Hana ʻia kā mākou huahana me ka hoʻohana ʻana i nā kaʻina hana hou e hōʻoia i ka maikaʻi kiʻekiʻe a me ke kūlike.Hoʻomaopopo mākou i ke koʻikoʻi o ka loaʻa ʻana o nā mea waena hilinaʻi a maʻemaʻe i ka hana lāʻau lapaʻau, ʻo ia ke kumu e kūpaʻa ai mākou i ka mālama ʻana i nā kūlana koʻikoʻi i ka wā o kā mākou hana hana.ʻO kā mākou tofacitinib intermediate 1,4-chloro-7-p-toluenesulfonyl-7H pyrrolo [2,3-d] pyrimidine e hoʻomaʻemaʻe ikaika, kūpaʻa a me ka hoʻāʻo palekana e hiki ai i kā mākou mea kūʻai ke hilinaʻi i ka hilinaʻi o ka synthesis nui o tofacitinib.
E koho iā mākou
Loaʻa iā JDK nā hale hana papa mua a me nā lako hoʻokele maikaʻi, e hōʻoiaʻiʻo ana i ka lako paʻa o nā kikowaena API.Hōʻoia ka hui ʻoihana i ka R&D o ka huahana.E kūʻē i nā mea ʻelua, ke ʻimi nei mākou iā CMO & CDMO ma ka mākeke kūloko a me ka honua.